Comparison of PTCy-based GvHD versus standard prophylaxis regimen in patients with hematologic malignancies

Graft-versus-host disease (GvHD) is the most common complication after transplantation in patients with hematologic malignancies and remains a major cause of morbidity and mortality in this population. Historically, the most common GvHD prophylaxis has been based on calcineurin inhibitor and a short course of methotrexate. Early phase studies have demonstrated the superiority of posttransplantation cyclophosphamide-tacrolimus-mycophenolate mofetil in GvHD prophylaxis in patients undergoing haploidentical transplantation.¹

We are pleased to a present a visual abstract summarizing the results of a phase III trial (NCT03959241) comparing posttransplantation cyclophosphamide (PTCy) based GvHD prophylaxis versus standard prophylaxis in patients with hematologic malignancies, published by Bolaños-Meade et al.¹ in The New England Journal of Medicine. The study demonstrated PTCy-based GvHD was superior to the standard GvHD prophylaxis with respect to GvHD-free survival and relapse-free survival in patients undergoing allogeneic hematopoietic stem cell transplantation.